Latest Headlines

Latest Headlines

Amgen nabs Kyprolis OK in Europe as U.S. competition mounts

Amgen's multiple myeloma treatment Kyprolis finally won approval in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time.

Amgen looks to Europe for Kyprolis boost as it battles Pomalyst, Darzalex at home

It's been more than three years since Amgen's multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech.

Amgen nabs another PCSK9 exclusive, this time with giant CVS

Amgen's PCSK9 med Repatha and Sanofi and Regeneron's competitor Praluent may have both nabbed coverage from top PBM Express Scripts. But now, Amgen has inked an exclusive pact with the giant's archrival, CVS.

Amgen's Repatha scores an exclusive with CVS

In the jockeying for share in the brand-new market for the specialized PCSK9 cholesterol-lowering meds, Amgen has picked up an edge over Sanofi by nailing a formulary exclusive with CVS. To get that preferred spot, Amgen has again agreed to tie the price of the drug to its effectiveness.

Samsung and Biogen verge on EU approval with an Enbrel biosimilar

Samsung Bioepis is months away from winning European clearance to market a copy of Amgen and Pfizer's blockbuster rheumatoid arthritis treatment Enbrel, securing a positive recommendation from EU regulators.

U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha

Amgen got a thumbs-down from U.K. cost watchdog the National Institute for Health and Care Excellence (NICE) for its PCSK9 cholesterol-fighter Repatha (evolocumab), bad news for the drug as it contends with pricing pushback and competes head-to-head with Sanofi and Regeneron's Praluent for market share.

Novartis takes a third biosimilar shot at Amgen with a copy of the blockbuster Neulasta

Novartis is moving toward the U.S. market with a biosimilar of Amgen's Neulasta, awaiting FDA approval for a long-acting treatment designed to boost white blood cell count.

Activist investor's new advice for Amgen: Merge with Allergan

Dan Loeb, the activist investor who once called for Amgen to break itself in two, is now advising the Big Biotech to consider merging with Allergan, according to Bloomberg.

Novartis, Roche CEOs see performance-based future, but U.S. isn't ready yet

Amgen may have pulled off a pay-for-performance pricing deal on its pricey new cholesterol drug Repatha with Boston-based Harvard Pilgrim. But other outcomes-based pricing negotiations haven't been as successful, and there are major reasons why.

With $10B deal hunt, Amgen looks even more like Big Pharma

Amgen has been edging toward a Big Pharma qualification for some time--not only with annual revenues that last year surpassed Eli Lilly & Co. and Bristol-Myers Squibb, but with investor-friendly trappings like dividends, buybacks and billion-dollar cost cuts.